Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Followed by Phase II Expansion Trial of Combination of Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (ComPACT)

NCT05491083 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05491083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05491083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Followed by Phase II Expansion Trial of Combination of Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (ComPACT)
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 12, 2023
Completion date
December 31, 2026
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, triple negative breast cancer